Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313366390> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4313366390 endingPage "196.1" @default.
- W4313366390 startingPage "196.1" @default.
- W4313366390 abstract "Abstract Objectives of this placebo-controlled study were to assess the safety and tolerability of single dose ANB020 administration in peanut-allergic adult patients and to measure the response during a standardized oral food challenge (OFC) after ANB020 or placebo administration compared to baseline peanut food challenge. On Day 1, fifteen highly allergic adult patients were administered 300 milligrams of ANB020 by IV infusion, and five patients were administered placebo injections. To measure patient response, patients were administered ex-vivo whole blood peanut antigen challenges on Day 2 and Day 5 and were administered OFCs on Day 15 and Day 45. The clinical outcomes and cellular responses of patients were analyzed. For patients given ANB020, 0% at Baseline, 67% on Day 15, and 57% on Day 45 passed the OFC; no placebo patients passed the OFC at Baseline, Day 15, or Day 45. Patients given ANB020 also experienced fewer adverse events (abdominal pain, nasal congestion), compared to placebo patients (abdominal pain, vomiting, nausea, asthma, allergic reaction). The median percentages of IL-4 and IL-9 cells in CD69 T cells were lower for patients administered ANB020 compared to patients administered placebo at Baseline, Day 2, and Day 5, and higher at Day 15. Peanut-specific and histamine skin test wheal sizes among all patients stayed consistent, except at Day 15 for patients given ANB020, where both wheal sizes decreased significantly to less than 5 mm. Volumes of peanut-specific IgE and total IgE were smaller for patients given ANB020 at Baseline, Day 15, and Day 45. Thus, study results show ANB020 injections to be potentially helpful in increasing patient tolerability and safety during OFCs." @default.
- W4313366390 created "2023-01-06" @default.
- W4313366390 creator A5003671742 @default.
- W4313366390 creator A5024150002 @default.
- W4313366390 creator A5028760615 @default.
- W4313366390 creator A5035178678 @default.
- W4313366390 creator A5082991251 @default.
- W4313366390 creator A5087990463 @default.
- W4313366390 date "2019-05-01" @default.
- W4313366390 modified "2023-09-26" @default.
- W4313366390 title "Randomized Controlled Phase 2a Study Results Using Anti IL-33 in Food Allergy" @default.
- W4313366390 doi "https://doi.org/10.4049/jimmunol.202.supp.196.1" @default.
- W4313366390 hasPublicationYear "2019" @default.
- W4313366390 type Work @default.
- W4313366390 citedByCount "0" @default.
- W4313366390 crossrefType "journal-article" @default.
- W4313366390 hasAuthorship W4313366390A5003671742 @default.
- W4313366390 hasAuthorship W4313366390A5024150002 @default.
- W4313366390 hasAuthorship W4313366390A5028760615 @default.
- W4313366390 hasAuthorship W4313366390A5035178678 @default.
- W4313366390 hasAuthorship W4313366390A5082991251 @default.
- W4313366390 hasAuthorship W4313366390A5087990463 @default.
- W4313366390 hasConcept C126322002 @default.
- W4313366390 hasConcept C141105273 @default.
- W4313366390 hasConcept C142724271 @default.
- W4313366390 hasConcept C159654299 @default.
- W4313366390 hasConcept C197934379 @default.
- W4313366390 hasConcept C203014093 @default.
- W4313366390 hasConcept C204787440 @default.
- W4313366390 hasConcept C207480886 @default.
- W4313366390 hasConcept C27081682 @default.
- W4313366390 hasConcept C2776027960 @default.
- W4313366390 hasConcept C2776203516 @default.
- W4313366390 hasConcept C2777903966 @default.
- W4313366390 hasConcept C2778375690 @default.
- W4313366390 hasConcept C2780580376 @default.
- W4313366390 hasConcept C2780852908 @default.
- W4313366390 hasConcept C2780955771 @default.
- W4313366390 hasConcept C42219234 @default.
- W4313366390 hasConcept C71924100 @default.
- W4313366390 hasConcept C90924648 @default.
- W4313366390 hasConceptScore W4313366390C126322002 @default.
- W4313366390 hasConceptScore W4313366390C141105273 @default.
- W4313366390 hasConceptScore W4313366390C142724271 @default.
- W4313366390 hasConceptScore W4313366390C159654299 @default.
- W4313366390 hasConceptScore W4313366390C197934379 @default.
- W4313366390 hasConceptScore W4313366390C203014093 @default.
- W4313366390 hasConceptScore W4313366390C204787440 @default.
- W4313366390 hasConceptScore W4313366390C207480886 @default.
- W4313366390 hasConceptScore W4313366390C27081682 @default.
- W4313366390 hasConceptScore W4313366390C2776027960 @default.
- W4313366390 hasConceptScore W4313366390C2776203516 @default.
- W4313366390 hasConceptScore W4313366390C2777903966 @default.
- W4313366390 hasConceptScore W4313366390C2778375690 @default.
- W4313366390 hasConceptScore W4313366390C2780580376 @default.
- W4313366390 hasConceptScore W4313366390C2780852908 @default.
- W4313366390 hasConceptScore W4313366390C2780955771 @default.
- W4313366390 hasConceptScore W4313366390C42219234 @default.
- W4313366390 hasConceptScore W4313366390C71924100 @default.
- W4313366390 hasConceptScore W4313366390C90924648 @default.
- W4313366390 hasIssue "1_Supplement" @default.
- W4313366390 hasLocation W43133663901 @default.
- W4313366390 hasOpenAccess W4313366390 @default.
- W4313366390 hasPrimaryLocation W43133663901 @default.
- W4313366390 hasRelatedWork W14180436 @default.
- W4313366390 hasRelatedWork W1974532828 @default.
- W4313366390 hasRelatedWork W1982089628 @default.
- W4313366390 hasRelatedWork W2017405920 @default.
- W4313366390 hasRelatedWork W2035049801 @default.
- W4313366390 hasRelatedWork W2046801408 @default.
- W4313366390 hasRelatedWork W2164244483 @default.
- W4313366390 hasRelatedWork W2372442000 @default.
- W4313366390 hasRelatedWork W2394317912 @default.
- W4313366390 hasRelatedWork W2985962552 @default.
- W4313366390 hasVolume "202" @default.
- W4313366390 isParatext "false" @default.
- W4313366390 isRetracted "false" @default.
- W4313366390 workType "article" @default.